Akoya Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Akoya Biosciences şirketinin toplam hissedar öz sermayesi $22.2M ve toplam borcu $75.7M olup, bu da borç-öz sermaye oranını 340.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $143.7M ve $121.5M dir.

Anahtar bilgiler

340.2%

Borç/özkaynak oranı

US$75.68m

Borç

Faiz karşılama oranı	n/a
Nakit	US$45.22m
Eşitlik	US$22.25m
Toplam yükümlülükler	US$121.50m
Toplam varlıklar	US$143.75m

Son finansal sağlık güncellemeleri

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28

Recent updates

Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Oct 08

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Jun 27

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

May 10

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AKYA 'nin kısa vadeli varlıkları ( $89.5M ) kısa vadeli yükümlülüklerini ( $32.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: AKYA şirketinin kısa vadeli varlıkları ( $89.5M ) uzun vadeli yükümlülüklerini ( $88.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AKYA 'nin net borç/öz sermaye oranı ( 136.9% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: AKYA şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AKYA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: AKYA tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Akoya Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Recent updates

Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler-Fusion 2.0 System and the new Phenocode Discovery IO60 Panel from Akoya Biosciences

Akoya Biosciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Akoya Biosciences, Inc. Announces Board Changes

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Akoya Biosciences, Inc. Updates Earnings Guidance for the Full Year of 2024

New major risk - Share price stability

Akoya Biosciences, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Consensus EPS estimates fall by 31%

Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024

Price target decreased by 11% to US$8.17

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Akoya Biosciences and Shanghai KR Pharmtech Announces Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

Akoya Biosciences, Inc., Annual General Meeting, Jun 04, 2024

Akoya Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

Consensus EPS estimates upgraded to US$0.83 loss

Full year 2023 earnings: EPS exceeds analyst expectations

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Akoya Biosciences, Inc. to Report Q4, 2023 Results on Mar 04, 2024

High number of new directors

Akoya Biosciences Deploys the Maxfuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory At Stanford University for Multiomic Integration of Spatial and Single-Cell Data on the Enable Medicine Platform

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 and for the Fiscal Year 2024

Price target decreased by 11% to US$9.25

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Consensus EPS estimates upgraded to US$1.46 loss

New minor risk - Share price stability

Price target decreased by 8.3% to US$11.00

Akoya Biosciences, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023

Price target decreased by 7.1% to US$13.13

Akoya Biosciences, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Akoya Biosciences, Inc. Launches PhenoCycler-Fusion 2.0 and Phenoimager HT 2.0 Platform Upgrades

Chief Operating Officer recently bought US$92k worth of stock

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Price target decreased by 12% to US$14.14

Akoya Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Price target decreased by 8.6% to US$16.00

New minor risk - Share price stability

Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million.

Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million.

Akoya Biosciences, Inc. Announces Executive Changes

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 7.9% to US$17.50

Consensus EPS estimates fall by 11%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Akoya Biosciences, Inc. to Report Q4, 2022 Results on Mar 06, 2023

Akoya Biosciences, Inc. to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Fiscal Year 2022

Chief Financial Officer exercised options to buy US$2.2m worth of stock.

Chief Financial Officer exercised options and sold US$298k worth of stock

President exercised options and sold US$59k worth of stock

Co-Founder recently sold US$67k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder recently sold US$325k worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akoya Biosciences, Inc Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy

Akoya Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Co-Founder recently sold US$319k worth of stock

President exercised options and sold US$63k worth of stock

Price target increased to US$20.40

Consensus forecasts updated

Akoya Biosciences, Inc. Raises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akoya Biosciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Price target decreased to US$18.60

President notifies of intention to sell stock